The CDK9 kinase in association with Cyclin T is a component of the transcription positive-acting complex pTEFb which facilitates the transition from abortive to productive transcription elongation by phosphorylating the carboxyl-terminal domain of RNA polymerase II. The Cyclin T1/CDK9 complex is implicated in Tat transactivation, and it has been suggested that Tat functions by recruiting this complex to RNAPII through cooperative binding to RNA. Here, we demonstrate that targeted recruitment of Cyclin T1/CDK9 kinase complex to speci®c promoters, through fusion to a DNA-binding domain of either Cyclin T1 or CDK9 kinase, stimulates transcription in vivo. Transcriptional enhancement was dependent on active CDK9, as a catalytically inactive form had no transcriptional eect. We determined that, unlike conventional activators, DNA-bound CDK9 does not activate enhancerless TATA-promoters unless TBP is overexpressed, suggesting that CDK9 acts in vivo at a step subsequent to TFIID recruitment DNA-bound. Finally, we determined that CDK9-mediated transcriptional activation is mediated by preferentially stimulating productive transcription elongation.
Introduction
The majority of known cyclin-dependent kinases (CDKs) have been described as cell cycle regulators, but some CDKs appear to have a direct role in transcription (Dynlacht, 1997) . Distinct cyclin-dependent kinases have been identi®ed in yeast and mammalian RNA polymerase II (RNAPII) complexes and they are able to phosphorylate the C-terminus domain (CTD) of the large subunit of eukaryotic RNAPII (Liao et al., 1995; Maldonado et al., 1996) . Three human CDKs (CDK7, CDK8 and CDK9) appear to regulate transcription by phosphorylating the CTD. Phosphorylation of RNAPII is an important rate limiting step for ecient elongation of RNAPII transcripts shortly after initiation (Dahmus, 1996) . CDK7 and its yeast homolog Kin28 are subunits of the basal transcription factor TFIIH (Feaver et al., 1994; Roy et al., 1994) . CDK8 and its yeast homolog Srb10 are components of the RNAPII holoenzyme (Maldonado et al., 1996; Rickert et al., 1996; Tassan et al., 1995) . The more recently described CDK9 kinase, previously named PITALRE (Grana et al., 1994; De Falco and Giordano, 1998) , is a component of the transcription positive-acting complex P-TEFb which facilitates the transition from abortive to productive transcription elongation through phosphorylation of the CTD (Marshall et al., 1996; Marshall and Price, 1995) . CDK9 is the kinase component of P-TEFb and by analogy with other CDKs, it has been found to be associated with a cyclin related partner called Cyclin T (Peng et al., 1998a,b; Wei et al., 1998) . Several lines of evidence have been recently presented indicating that P-TEFb is required for Tat-transactivation of the HIV-1 promoter (Fujinaga et al., 1998; Mancebo et al., 1997; Wei et al., 1998; Zhou et al., 1998; Zhu et al., 1997) . It has been shown that Cyclin T binds on its own and in association with CDK9 to the activation domain of Tat and most importantly Cyclin T increases the anity of Tat for TAR (Wei et al., 1998; Zhou et al., 1998) . It has been proposed that Tat upon binding to TAR, recruits the Cyclin T/CDK9 complex leading to hyperphosphorylation of the CTD of RNAPII (Jones, 1997) . Thus, recruitment of CyclinT/CDK9 kinase to RNAPII may represent an important rate-limiting step in transcription. Here, we describe evidences that the recruitment of Cyclin T1/ CDK9 kinase complex to promoter template, through fusion to a DNA-binding domain of components of the kinase complex, stimulates transcription of RNAPIIdependent promoters bearing the cognate DNAbinding sites in vivo, and the arti®cially DNA-bound CDK9 kinase functions in transcription at a step subsequent to TFIID recruitment by enhancing transcription elongation.
Results
Recruitment of Cyclin T1/CDK9 kinase complex to promoter DNA enhances transcription Consistent with the proposed general role of CyclinT1-CDK9 complex in transcription (Marshall et al., 1996; Marshall and Price, 1995; Peng et al., 1998a,b) we found that over-expression of both proteins in transient transfections induced a modest but signi®cant increase of transcription driven from various RNAPII promoters such as HIV-1 LTR, SV40 early and human c-myc promoters, Figure 1a . Thus, enforced expression of both Cyclin T1 and CDK9 proteins, most likely as subunits of the P-TEFb, enhances the expression of several RNAPII promoters in vivo. Clearly, the lack of promoter speci®city for CyclinT1/CDK9 complex poses a severe limitation for functional studies of these factors in the regulation of transcription in vivo. To examine the role of CyclinT1/CDK9 in transcription in a promoter speci®c manner we fused the Cyclin T1 and CDK9 proteins to a sequence-speci®c DNAbinding domain (GAL4-1-147) and tested the ability of the fusion proteins to modulate transcription in vivo of promoters containing appropriate GAL4 DNA-binding sequences. The G5-SV40, G5-83-HIV, G5-38-HIV, G5-c-myc and G5E1b promoters all bearing ®ve GAL4 DNA-binding sites (Majello et al., 1997) , were used as reporters. As shown in Figure 1b arti®cial recruitment of either CyclinT1 or CDK9 via GAL4 DNA-binding sites eectively stimulated transcription from the G5-SV40, G5-83-HIV and G5-c-myc promoters. In contrast, no detectable activation was found when the G5-38-HIV and G5E1b promoters were used ( Figure  1b) . Moreover, transcription activations were speci®c to reporter plasmids containing GAL4 sites with no activation being observed on isogenic reporter plasmids lacking such sites (data not shown).
Next, various GAL4-CyclinT1 fusions were constructed in order to de®ne speci®c regions required for activation. As reported in Figure 2a , we found that progressive deletions of the C-terminus aected activation. GAL4-CycT(1-593) and GAL4-CycT(1-420) retain the activating function albeit at a much lower level comparing to the wild type. In contrast, GAL4-CycT(1-290) failed to activate transcription. Thus, it appears that regions at C-terminus are important for proper functioning of the protein.
Finally, the ability of the GAL4-CyclinT1 fusion protein to activate transcription was abolished when the N-terminus cyclin box region was deleted , suggesting that the cyclin homology region is strictly required for activation. In vitro binding assays have shown that the region of Cyclin T containing the cyclin homology box (aa 1 ± 263) is sucient for ecient binding to CDK9 (Peng et al., 1998a,b) . On the other hand this region alone was not sucient to activate transcription when fused to GAL4 DBD, suggesting that additional regions at the Cterminus are required for functioning. Accordingly with our in vivo results it has been reported that albeit the cyclin box region is sucient for ecient interaction with CDK9 kinase, the resulting complex has a very low kinase activity in vitro and activates transcription in vitro at a very low level (Peng et al., 1998a,b) .
The requirement for the cyclin-box in transcription activation strongly suggests that GAL4-CyclinT1 recruits the endogenous CDK9 kinase to the promoter. To determine the role of CDK9 in the function of GAL4-CyclinT1, we performed a squelching experiment. Previous data have shown that catalytic inactive CDK9 protein (CDK9dn) bearing a single amino acid change of Asp167 to Asn is functionally able to associate in vitro and in vivo with Cyclin T (Zhou et al., 1998; De Falco and Giordano, 1998) . We reasoned that if CDK9 is required for GAL4-CyclinT1 activation, coexpression of CDK9dn would prevent the endogenous CDK9 protein from interacting with GAL4-CyclinT1. As presented in Figure 2b , coexpression of CDK9dn eectively inhibited activation by GAL4-CyclinT1 in a dose-dependent manner. Moreover, expression of CDK9dn protein had no eect on the basal promoter activity. In contrast, coexpression of native CDK9 did not interfere with GAL4-CyclinT1 activation ( Figure  2b , lanes 7 ± 9).
Our ®ndings strongly suggest that GAL4-CyclinT1 fusion aects transcription by recruiting the CDK9 kinase to the promoter. In line with these considerations we determined that direct recruitment of the CDK9 kinase to promoter DNA eectively activates transcription. In contrast, GAL4-CDK9dn failed to do so, indicating that the kinase activity of CDK9 is essential for transcription activation (Figure 3a) . Western blot analysis of the transfected cells demonstrated that both GAL4-CDK9 and GAL4-CDK9dn proteins were expressed at similar levels ( Figure 3b ). Finally, recruitment of CDK5, a cyclin-dependent kinase not involved in the phosphorylation of CTD, did not aect promoter activity (Figure 3a) . Results similar to those presented in Figure 3a were also found Transcription activation by CDK9 kinase recruitment B Majello et al using the G5-SV and the G5-c-mycXDN promoters (data not shown).
Next, we sought to determine whether in vivo association of GAL4-CDK9 with the endogenous Cyclin T1 is required for activation. Since it has been found that the cyclin homology box (aa 1 ± 263) of Cyclin T1 is sucient for ecient binding to CDK9 (Peng et al., 1998a) , we reasoned that enforced expression of a Cyclin T1 region (1 ± 290) encompassing the cyclin homology region (aa 1 ± 286) would compete with the endogenous Cyclin T1 for binding to CDK9, while over-expression of the wild type cyclin T1 would enhance the GAL4-CDK9 activation if the amount of endogenous cyclinT1 is limiting in the cell. As shown in Figure 3c , we found that coexpression of CMV-CyclinT1 with GAL4-CDK9 increased the GAL4-CDK9 activity in a dosedependent manner. Conversely a dose-dependent inhibition was found when the cyclin homology region of Cyclin T1 (1 ± 290) was coexpressed with GAL4-CDK9. Importantly, expression of either CMV-CycT or CMV-CycT (1 ± 290) had no eect on the basal promoter activity. Finally, we found that increased levels of native CDK9 interfere with activation by GAL4-CDK9 (Figure 3c , lanes 11 ± 13). The ability of native CDK9 to interfere with GAL4-CDK9 activation is likely due to competition for association with endogenous Cyclin T1.
Taken together our results indicated that enforced recruitment of the CyclinT1/CDK9 complex to promoter DNA sequences eectively activates transcription and the kinase activity of CDK9 is strictly required for activation.
CDK9 kinase acts in vivo at a step subsequent TBP recruitment
Our ®ndings demonstrated that targeted recruitment of CDK9 kinase to a promoter activates in vivo transcription. However, when the activation capability of either GAL4-CyclinT1 or GAL4-CDK9 fusions were tested using the promoters G5-38HIV and G5-E1b both lacking of promoter upstream elements, transactivation was barely detectable (Figure 1b) . Thus, deletion of the three Sp1 DNA-binding sites from the HIV-1 promoter strongly aected GAL4-CDK9 activation. Therefore, neither GAL4-CyclinT1 nor GAL4-CDK9 function as conventional DNAbound activators, while a number of GAL4-fusions with de®ned conventional activator domains (VP16, E1a, Myc, p65, E2F, SP1) eectively stimulate transcription from the same reporters (data not shown). Since both the G5-38HIV and G5-E1b promoters contain only the TATA-box sequence, we reasoned that the lack of activation by either GAL4-CDK9 and GAL4-CyclinT1 might be due to the fact that CyclinT/CDK9 complex aects only the elongation step with no signi®cant role in recruiting components of the preinitiation complex (PIC). A large number of studies have demonstrated that in vivo recruitment of TBP to a TATA-box containing promoter is an important limiting-step for transcription activation (Ptashne and Gann, 1997) . Therefore, we sought to test whether enforced expression of hTBP might suce for activation mediated by the GAL4-CyclinT1 or GAL4-CDK9. The fusion proteins were then assayed in the presence of enforced expression of hTBP. As reported in Figure 4a , while enforced expression of hTBP had only a modest eect on transcription from the G5-E1b promoter, co-expression of hTBP together with either GAL4-CyclinT1 or GAL4-CDK9 resulted in a very strong transcriptional activation. In addition, synergy between hTBP and CDK9 strictly requires the kinase activity of the protein since GAL4-CDK9dn did not co-operate with hTBP.
Synergy between CDK9 and TBP was further assayed using a DNA-bound hTBP. Studies from dierent laboratories have demonstrated that arti®cial recruitment of TBP to a promoter induces transcription in the absence of any activator (Gonzalez-Couto et al., 1997; He and Weintraub, 1998; Majello et al., 1998a,b; Xiao et al., 1997) . We reasoned that a factor that functions at a step subsequent to TBP recruitment should act in concert with DNA-bound-hTBP and further stimulate transcription. Thus, we tested whether enforced recruitment of both hTBP and CDK9 to promoter DNA would result in a synergistic activation. We used the pTetR-hTBP expression vector (Majello et al., 1998b) in which the hTBP core sequences (aa 106 ± 339) were connected in frame to the C-terminus of the prokaryotic TetR encoded by Tn10 from Escherichia coli. Thus, the TetR-hTBP chimeric protein is able to bind to the Tet operator (TetO) sequences. Coexpression of GAL4-CDK9 and TetR-hTBP was evaluated by co-transfections using as reporter the G5-TetO-E1b plasmid which contains the CAT gene under the control of the E1b TATA box with a single tetO sequence and ®ve GAL4 DNA-binding sites. The G5-TetO-E1b reporter permits arti®cial docking of both GAL4 and TetR fusion proteins, thereby recruiting both GAL4-CDK9 and TetR-hTBP fusion factors to a TATA-box promoter proximal location. Accordingly with previous results we found that the TetR-hTBP Figure 3 Schematic representation of the GAL4 fusion constructs is presented on the top, dn indicate dominant negative and a small box indicates the location of the mutation. (a) G5-83HIV reporter (1 mg) was cotransfected into 293T cells with the indicated GAL4 expression vector (4 mg). The Western blot (b) with GAL4 antibody displays the relative level of expression of GAL4-CDK9 and GAL4-CDK9dn proteins in transfected cells. In (c) G5-831HIV reporter (1 mg) was cotransfected into 293T with a constant amount of GAL4-CDK9 (4 mg) together with dierent amounts of CMV-CycT (2-6-10 mg in lanes 4, 5, 6), CMV-CycT (1 ± 290) (2, 6, 10 mg in lanes 8, 9, 10) and CMV-DCK9 (2-6-10 mg in lanes 11, 12, 13), respectively. In lanes 2 and 7, G5-831HIV reporter (1 mg) was transfected with 10 mg of CMV-CycI T or CMV-CycT (1 ± 290), respectively. For both a and c panels, data are presented as fold activations relative to the sample without eector. Each histogram bar represents the mean of at least three independent transfections Transcription activation by CDK9 kinase recruitment B Majello et al activates transcription, however, co-expression of GAL4-CDK9 resulted in a robust synergistic eect (Figure 4b ). These ®ndings strongly suggest that the synergy between CDK9 and hTBP is likely due to the concerted action of two diverse stimulatory factors aecting dierent rate-limiting step in transcription.
GAL4-CDK9 induces processive transcription in vivo
Previous studies have shown that recombinant CyclinT-CDK9 complex possessed a DRB-sensitive kinase activity and functioned in transcription elongation in vitro (Peng et al., 1998a,b; Wei et al., 1998; Zhou and Sharp, 1996) . Having de®ned that CDK9 kinase when fused to a DNA-binding domain functions as a transcriptional activator at a step subsequent to TFIID recruitment, we sought to determine whether the recruitment of CDK9 kinase in vivo would aect transcription initiation, elongation or both. To this end we carried out transient transfections using the G5-83HIV reporter in the presence of Tat and/or GAL4-CDK9 and promoter activity was monitored by CAT measurements and RNase protection assays. The use of the HIV LTR promoter is instrumental for the in vivo analysis of levels of transcription initiation versus elongation. Transcription from the HIV LTR, in the Figure 4 Synergy between hTBP and CyclinT or CDK9 proteins recruited to promoter DNA. In a, is reported the results of cotransfections into 293T cells using the G5-E1b reporter (1 mg) in the presence of the indicated eectors (2 mg). In b, is reported the assays demonstrating the functional cooperation between hTBP and CDK9 tethered to promoter DNA. On the left a schematic representation of the eector and reporter plasmids is shown. The G5-TetO-E1b (1 mg) was transfected into 293T cells together with the indicated eector (2 mg). In both panels the data are presented as fold activation relative to the sample without eector absence of Tat, gives rise to primarily short, abortive transcripts 55 ± 70 nucleotides in length (Jones and Peterlin, 1994) . In the presence of Tat, transcription is highly processive resulting in full-length polyadenylated transcripts that protect a 101-nucleotides long RNA probe in our RNase protection assays. Consequently, the ratio of long versus short transcripts can be used to estimate the eciency of transcription elongation. As presented in Figure 5a , HIV LTR promoter activity was enhanced at comparable levels by Tat and GAL4-CDK9 and co-expression of both activators caused a further stimulation of HIV LTR driven gene expression. To examine at which transcriptional step the GAL4-CDK9 was acting, RNA was isolated from the same transfected cells examined for CAT activity, and the results of the RNase protection assays are presented in Figure 5b . We found that in the absence of any activator, transcription from the HIV promoter mainly induced short transcripts and the long productive transcripts were barely detectable (lane 1). As expected, Tat dramatically induced the long processive transcripts (lane 4). Signi®cantly, recruitment of CDK9 by GAL4 fusion induced mainly the processive transcripts. Thus, the GAL4-CDK9 enhanced promoter activity in vivo by aecting the transition from abortive to productive RNAPII transcripts. Moreover, co-expression of Tat and GAL4-CDK9 stimulates only progressive transcripts, while the short non productive transcripts were unaected (Figure 5b , compare lanes 2 with 3 and 4).
These data strongly suggest that arti®cial recruitment of CDK9 kinase to the HIV-1 promoter activates transcription by enhancing the generation of progressive transcripts. In contrast, it has been recently shown (Xiao et al., 1997; Majello et al., 1998a,b) that arti®cial recruitment of TBP to the HIV-1 promoter, which is likely to increase the eciency of PIC formation, is insucient for enhancing synthesis of full-length transcripts to the level observed with GAL4-CDK9. Hence, it appears that unlike other general transcription factors such as TBP, tethering of CDK9 to a promoter enhances transcription by aecting elongation rather than initiation.
Discussion
We presented here a series of functional assays that were designed to address the role of Cyclin T1/CDK9 kinase complex in transcription in vivo. When the results of each assay are considered all together they strongly suggest that in vivo: (i) recruitment of Cyclin T/CDK9 kinase is an important rate-limiting step for transcription of many RNAPII promoters; (ii) DNAbound CyclinT1 requires association with endogenous CDK9 for activation and the CDK9 kinase activity is required for functioning; (iii) unlike conventional activators, DNA-bound CDK9 does not activate enhancerless TATA-promoters unless TBP is overexpressed, suggesting that CDK9 acts in vivo at a step subsequent to TFIID recruitment; (iv) tethering of CDK9 kinase to a promoter template stimulates transcription elongation.
The ability of DNA-bound CDK9 kinase to enhance transcription is strictly dependent on the CDK9 catalytic function. This result is consistent with the suggestion that phosphorylation of the CTD of RNAPII can facilitate transcription. Moreover, the observation that GAL4-CDK9 can synergize with TBP suggests further that CDK9 modulate transcription in vivo at post-initiation events. Albeit we do not provide evidence that the eect of DNA-bound CDK9 kinase is mediated by CTD phosphorylation, it seems the most favorable hypothesis. Consistent with the proposal that CDT phosphorylation is a regulatory event that can facilitate transcription elongation, we found that CDK9 kinase transcriptional activation is mediated by a preferential stimulation of productive rather than abortive transcription.
In a recent work reported that CDK8 kinase, which like CDK9 is able to phosphorylate the CTD of RNAPII, can activate transcription in a catalysis-dependent manner when it is targeted to a promoter-proximal RNA element. However, unlike CDK9, the DNA-bound CDK8 fusion is able to activate transcription in a catalytic-domain independent manner (Gold et al., 1996) . Since CDK8 is associated with the RNAPII holoenzyme (Tassan et al., 1995; Rickert et al., 1996) , it has been suggested that CDK8 does not require enzymatic function to associate with RNAPII holoenzyme (Gold et al., 1996; .
Clearly the presence of diverse CDKs able to function after initiation to modulate transcription represents a novel and intricate layer of regulation of gene expression. To date, Tat-mediated transactivation represents the most well documented example of the involvement of a kinase complex in transcription regulation. It has been established that the Cyclin T1/ CDK9 complex is recruited to promoter-proximal RNA sequences via Tat-mediated binding to TAR (Fujinaga et al., 1998; Mancebo et al., 1997; Wei et al., 1998; Zhou et al., 1998; Zhu et al., 1997) . How cellular promoters, which are regulated by attenuation, such as c-myc, c-myb and c-fos, recruit speci®c kinase complexes to RNAPII remains to be investigated. The ability of the Cyclin T1/CDK9 kinase to function in a catalytic-dependent manner when bound to promoter upstream sequences raises the possibility that promoter-speci®c activation of transcription elongation might occur through interaction between CyclinT/CDK9 complex and a dedicated DNA-bound activator.
Materials and methods

Tissue culture and transfections
Human 293T and HeLa cells were grown in Dulbecco's modi®ed Eagle's medium (DMEM) supplemented with 10% fetal calf serum. Transfections were performed by calcium phosphate precipitation using subcon¯uent cell cultures (10 cm dishes) with dierent amounts of reporter and eector plasmids as reported in the text. For normalization of transfection eciencies 1 mg b-Gal expression plasmid (pSV-b-Gal expression plasmid, Promega) was included in the cotransfections (except for the transfections reported in Figure 1a ), and total amount of DNA (10 mg) was kept constant with CMV empty vector DNA. CAT assays were performed with dierent amounts of extract to ensure linear conversion of the chloramphenicol with each extract and results are presented as the means of at least four independent transfection experiments. Standard deviations were less than 10%. The CAT activity was quanti®ed using the Molecular Dynamics PhosphorImager System TM . Western blot analysis was carried out using anti-GAL4 antibody (Upstate Bio., Inc), and antibody binding was visualized by enhanced chemiluminescence (ECL-plus kit, Amersham).
Plasmids
pRC/CMV-CDK9 and pRC/CMV-CDK9n have been described (Garriga et al., 1996) . The pRc/CMV-Cyclin T was constructed by inserting the EcoRI ± NcoI fragment from GST-CyclinT containing the full-length CyclinT1 cDNA into the EcoRV site of pCDNA3 (Invitrogen) via blunt ligation. The same fragment was inserted into the SmaI site of pSG424 to obtain the GAL4-CyclinT1. GAL4-CycT (1 ± 290) was constructed by EcoICRI digestion and religation of the GAL4-CyclinT1. To construct the GAL4-CycT (290 ± 726) the EcoICRI fragment encoding the region from amino acids 290 ± 726 was cloned into the SmaI site of pSG424. The GAL4-CycT (1 ± 420) was obtained by inserting the EcoRI ± NdeI fragment from GAL4-CyclinT1 into the EcoRI ± EcoICRI site of pSG424 via blunt ligation. The GAL4-CycT (1 ± 593) was constructed by inserting the EcoRI ± ScaI fragment from GAL4-CyclinT1 into the EcoRI ± EcoICRI site of pSG424. The CMV-CycT (1 ± 290) was obtained inserting the EcoRI ± EcoICRI fragment from GAL4-CycT (1 ± 290) into the EcoRI ± EcoRV sites of pCDNA3. GAL4-CDK9 was constructed by inserting the NcoI ± EcoRI fragment from GST-CDK9 bearing the full-length cDNA into the SmaI site of pSG424 via blunt ligation. In a similar way GAL4-CDK9dn was constructed with the NcoI ± EcoRI fragment derived from pRC/CMV-CDK9dn (Garriga et al., 1996) . The GAL4-CDK5 was obtained by inserting the SmaI fragment from GST-CDK5 containing the full length CDK5 cDNA into the EcoRI site of pSG424 via blunt ligation. pRC/CMVhTBP containing the full-length human TBP cDNA has been described (Majello et al., 1998a) . TetRhTBP were constructed by inserting the HincII fragment encoding the aa 106 ± 339 of the human TBP, in frame with the TetR DNA binding domain of the pTetR vector (Majello et al., 1998b) . Sequences of all the resulting plasmids were veri®ed by DNA sequencing for correct junctions.
The HIV-1 long terminal repeat (LTR)-based CAT plasmids G5-83-HIV and G5-38-HIV contain the LTR sequences from 783 to +82 and from 738 to +82 respectively with ®ve GAL4 binding sites inserted at position 783 (G5-83-HIV) and 738 (G5-38-HIV) (Majello et al., 1997) . The G5-myc-XDN is a CAT reporter containing the human c-myc promoter sequences from XhoI to NaeI (793 to +54 respect to the P2 transcription start site) with ®ve GAL4 DNA binding sites inserted at the XhoI. The G5-SV contains ®ve GAL4 DNA binding sites upstream the three 21 bp repeats of the SV40 early promoter (Majello et al., 1997) . The G5-TetO-E1b was made by inserting a double stranded oligonucleotide bearing a single TetR DNA-binding site between the ®ve GAL4 sites and the TATAA-box of G5-E1B reporter (Majello et al., 1998b) .
RNase protections
Forty-four hours after transfection cells were harvested and total RNA was isolated and 30 mg of RNA from transfected cells were used for the RNase protection assay. To make the HIV LTR probe the 270 bp-long PstI ± KpnI fragment from G5-83HIV, containing the GAL4 sequences fused to the LTR nucleotides from 783 to +82, was cloned into pGEM4Z and the SP6 polymerase was used to produce a-32 P-GTP-labeled RNA probe (Majello et al., 1998a,b) . Protected fragments were separated on a 8% polyacrylamide/7M urea sequencing gel and analysed using the Molecular Dynamics PhosphorImager System TM .
